Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents the first instance of recurrent flank alopecia in a Tibetan Terrier, diagnosed alongside atopic dermatitis.

This article discusses the challenges in diagnosing and treating diffuse hair loss in women and emphasizes the importance of distinguishing between androgenetic alopecia, chronic telogen effluvium, and psychogenic pseudo effluvium, but reports no new clinical results.

This letter reports on a case of intractable ophiasis-type alopecia areata that was presumably improved by fexofenadine, but no new clinical results are presented.

Teriflunomide can cause hair thinning.

In this case report, discontinuing leflunomide resolved chronic cutaneous ulcers in a 67-year-old woman, suggesting a potential link between long-term leflunomide use and ulcer formation.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This case study identified Geotrichum candidum as a cause of skin lesions in a horse following extended corticosteroid or antibiotic use, noting the importance of thorough diagnosis and specific antifungal treatment to improve symptoms.

In this clinical study, the researchers found that a standardized wheat polar lipid complex, in both oil and powder form, significantly reduced hair shedding and improved hair growth in 99 women with acute telogen effluvium over 56 to 84 days.

This article discusses the presentation of chemotherapy-induced anagen effluvium as either diffuse or patterned hair loss and reports no new clinical findings.

This study found that iron deficiency might play a role in the development of telogen effluvium in premenopausal women, highlighting the importance of checking hemoglobin in acute TE and serum ferritin in chronic TE.

This report suggests that a severe reaction involving dermatitis, alopecia, and fever in a patient receiving aurothioglucose was likely allergic, as indicated by clinical findings and a positive lymphocyte transformation test.

The conclusion cannot be provided because the document content is not available.

This study found that a dietary supplement containing L-cystine, medicinal yeast, and pantothenic acid significantly improved hair growth in women with telogen effluvium over six months compared to placebo.

In this case report, a patient with HIV developed hirsutism after starting tofacitinib for alopecia areata, which resolved upon medication discontinuation and laser hair removal.

This study reported that a 29-year-old woman with telogen effluvium experienced improved hair growth and reduced hair loss through 12 sessions of plum blossom acupuncture combined with electroacupuncture, as evidenced by new hair growth, improved hair-pull test results, and decreased telogen phase hair percentage.

COVID-19 patients with hair loss experienced more cognitive issues and these issues were linked to higher levels of depression, anxiety, and stress.

This meta-analysis found that iron deficiency is associated with telogen effluvium and identified critical serum ferritin levels for defining iron deficiency in these patients.

This study explored biochemical biomarkers in post-COVID-19 patients experiencing acute telogen effluvium, finding sex differences in blood characteristics and varying D-dimer levels by age, with elevated D-dimer showing correlations with inflammation markers.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

In this observational study, researchers found that women with telogen effluvium who had higher baseline ferritin levels or received higher doses and longer durations of iron supplementation reported greater satisfaction, suggesting that iron supplementation can improve patient satisfaction regardless of initial ferritin levels.

A simple method using the wash test and dermatoscopy can help differentiate between two hair loss conditions, androgenetic alopecia and chronic telogen effluvium.

In this case report, a 9-year-old horse was diagnosed with alopecia areata contributing to Malassezia dermatitis, involving lymphocyte infiltration and symptoms consistent with yeast presence.

This study found that female patients with telogen effluvium had significantly lower serum ferritin levels compared to healthy individuals, suggesting an association between low ferritin and this condition.

This study observed that LED therapy improved hair regrowth and reduced hair loss in patients with post-COVID telogen effluvium, with or without androgenetic alopecia, compared to those who did not receive LED treatment.

This study suggests that chemotherapy-induced anagen effluvium represents patterned hair loss, with most patients retaining hairlines, but patterns do not vary significantly by age, symptoms, or chemotherapy type.

Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.

This study observed that post-COVID patients, especially females, commonly experience Telogen Effluvium, with earlier onset and increased trichodynia in those with more severe COVID-19.

This study found that patients with Telogen Effluvium had significantly higher levels of scalp pain and itching, and serum ferritin levels could effectively differentiate them from healthy controls.